

Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Non-Small Cell Lung Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following statements best describes observations from the Phase III LUNAR trial investigating the addition of tumor treating fields to standard therapies for patients with metastatic non-small cell lung cancer who experience disease progression on or after platinum chemotherapy?**
 - Primary endpoint of significantly improved overall survival (OS) was not met
 - Primary endpoint of significantly improved OS was met
- 2. In the NeoCOAST platform study of neoadjuvant durvalumab with targeted therapy for resectable NSCLC, which of the following combinations demonstrated the greatest objective response rate?**
 - Durvalumab monotherapy
 - Durvalumab with oleclumab
 - Durvalumab with monalizumab
 - Durvalumab with danvatirsen
- 3. Which of the following best describes observations with lower- (5.4 mg/kg) and higher-dose (6.4 mg/kg) T-DXd in patients with HER2-mutated lung cancer in the Phase III DESTINY-Lung02 trial?**
 - Lower dose was more tolerable but less efficacious
 - Lower dose was similar in tolerability and efficacy
 - Lower dose was more tolerable and similarly efficacious
- 4. Which of the following regimens conferred the greatest median overall survival to patients with advanced NSCLC in a recently updated analysis of the CheckMate 227 trial?**
 - Nivolumab with ipilimumab
 - Nivolumab
 - Chemotherapy
- 5. Which of the following types of toxicities is most commonly reported with mobocertinib in patients with advanced NSCLC and EGFR exon 20 insertion mutations?**
 - Hematologic
 - Gastrointestinal
 - Ocular
 - Neurological